The global periodontal therapeutics market size is anticipated to reach USD 1.41 billion by 2030, growing at a CAGR of 7.2% over the forecast period, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of periodontal diseases aided by the growing geriatric population. According to an article published by NCBI, in September 2023, the percentage of older adults affected by the disease is anticipated to rise from 42.44% in 2020 to 54.57% by 2050. Mild periodontal diseases are predicted to continue being the most common type, accounting for 80.39% of cases. Additionally, the number of untreated cavities in teeth is expected to increase by 75.2% between 2020 and 2050.Market Report Highlights
• The chronic periodontal disease segment held the largest share of the market, attributed to the high treatment rate.
• The doxycycline drug type dominated the market. Doxycycline, even at lower concentrations, has been found to inhibit matrix metalloproteinase-8 (MMP-8), an enzyme abundant in periodontitis.
• Hospital pharmacies distribution channel held the largest share of the market. The high prescription rates at hospitals, high patient preference, and increasing number of patients visiting hospitals are driving the growth of this segment.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of the disease, and favorable regulatory environment.
Get deeper insights, latest developments & key market drivers in the Global Periodontal Therapeutics Market
Increasing awareness about oral health fuels the growth of the market. Numerous campaigns have been created using data from formative needs assessments, focusing on the widespread issue of poor dental health in various populations. Certain campaigns were tailored to specific demographics, including adults, children, parents of infants, and disadvantaged socio-economic groups considered to be at higher risk for dental problems.
The emergence of antibiotic-resistant strains of bacteria associated with periodontal diseases necessitates several key actions and considerations. For instance, in October 2022, a research study focused on assessing antimicrobial resistance in microorganisms associated with periodontal diseases underscores the importance of ongoing research in understanding the scope of resistance among these bacteria. This investigation highlights the necessity for developing targeted treatments and strategies to address antibiotic resistance effectively. The study emphasizes the detrimental impact of healthcare professionals on antimicrobial resistance due to indiscriminate prescribing of antimicrobials.
Key Players in the Periodontal Therapeutics Market
• Pfizer Inc.
• Lupin Ltd
• Teva Pharmaceuticals USA, Inc.
• Tokyo Chemical Industry Co., Ltd.
• Bausch Health Companies Inc.
• USAntibiotics
• Melinta Therapeutics LLC
• Cipla, Inc.
• Chartwell Pharmaceuticals LLC.
Looking for Periodontal Therapeutics Market Research Report? Get your free sample PDF with key data & latest trends.
Furthermore, Grand View Research has segmented the global periodontal therapeutics market based on disease, drug type, distribution channel, and region.